Immunoglobulin G4–related sclerosing disease of the paranasal sinuses: A case report and literature review

Nathan D. Vandjelovic, D.O.,1 and Ian M. Humphreys, D.O.2

ABSTRACT

Objective: Immunoglobulin G4 (IgG4) related sclerosing disease (RSD) of the paranasal sinuses is a rare lesion of dense lymphoplasmacytic tissue, with a high proportion of IgG4+/H11001 plasma cells. We presented a rare case of IgG4-RSD with isolated involvement of the paranasal sinuses in the absence of multiorgan involvement.

Methods: A case report and comprehensive literature review.

Results: To our knowledge, only 11 cases of IgG4-RSD with paranasal sinus involvement have been reported. Patients with IgG4-RSD commonly present with epistaxis and symptoms that mimic chronic rhinosinusitis, e.g., rhinorrhea, nasal obstruction, and facial pressure. On imaging, an expansive and erosive process is described. Surgery provides tissue for immunohistologic evaluation; however, there is a paucity of evidence about the direct extent of surgical resection or medical therapies. Postoperative steroids were typically started, although the regimen was not standardized.

Conclusion: Few cases of paranasal sinus IgG4-RSD have been reported in the literature. Evidence-based recommendations regarding treatment and surveillance of paranasal sinus IgG4-RSD are lacking; however, most reports describe systemic steroids as the mainstay of treatment. This single subject analysis, with a review of previously reported cases adds to the expanding body of data related to this rare disorder.

Humoral immunity is mediated by immunoglobulins secreted by plasma cells. There are four immunoglobulin G (IgG) isozymes, labeled 1 to 4; IgG4 accounts for <6% of the total IgG fraction in healthy subjects.1 The pathogenesis of IgG4–related sclerosing disease (RSD) has not been fully elucidated; however, an immune reaction, predominately mediated by T-helper type 2 and regulatory T cells, has been proposed.2 T-helper type 2 lymphocytes produce various interleukins, cytokines, and growth factors, which may result in chronic lymphoplasmacytic infiltration and fibrosis when produced in disproportionate amounts. Previously, Masaki et al.3 performed a retrospective review of 132 patients with systemic IgG4-RSD and described quantitative serologic criteria (Table 1). However, in a 2012 consensus statement, a diagnostic algorithm of IgG4-RSD was developed based primarily on the histologic characteristics of involved tissue, whereas serum IgG4 measurements were considered of secondary importance.4 Imaging, although not pathognomonic, is helpful in the workup of this lesion. IgG4-RSD that involves the sinonasal cavities is uncommon, with only a few cases previously described. We present a rare case of a patient with IgG4-RSD with isolated involvement of the paranasal sinuses in the absence of systemic disease.

CASE STUDY

A 46-year-old man presented to the otolaryngology clinic with recurrent right-sided epistaxis, facial pain, nasal congestion, rhinorrhea, and nasal crusting for 1 year. Review of systems and results of basic laboratory investigations (i.e., complete blood count and comprehensive metabolic panel) were unremarkable, and, therefore, there was low suspicion for systemic disease. No serum IgG4 measurements were collected. High-resolution computerized tomography (CT) of the sinuses revealed a well demarcated but expansive mass of the right ethmoid sinus with erosion of the lamina papyracea (Figs. 1 and 2). There was no evidence of infiltration within the surrounding structures (i.e., periorbita or skull base). Intraoperative endoscopic visualization confirmed the presence of a polypoid mass that primarily involved the right ethmoid sinus with extension into the frontal recess and erosion of the lamina papyracea. The periorbita and skull base were unaffected. The patient underwent endoscopic sinus surgery with excisional biopsy of the lesion.

Results of a histologic analysis of the sinus lesion demonstrated dense infiltrates of plasma cells and fibrosis deep within the tissue. Immunostain for CD138,
a generic plasma cell marker, labeled >50% of the visible cells (Fig. 3) and anti-IgG4 stains of the sinus lesion demonstrated >50% of the IgG4 subclass (Fig. 4). Postoperative management included oral antibiotics for 7 days, saline solution irrigations, and prednisone 30 mg per day for 4 weeks tapered by 5 mg per week until completed. Routine postoperative debridement in the office was performed. At 1-year of follow-up, there had been no endoscopic evidence of persistent or recurrent disease. All of the patient’s symptoms had resolved, without the need for continued therapy.

**LITERATURE REVIEW**

A search of the literature located only 11 cases of IgG4-RSD with sinonasal involvement (Table 2). In 2009, Ishida et al. described the first case of sinonasal IgG4-RSD. Including our case, IgG4-RSD of the paranasal sinuses affects men somewhat more often than women (7:5) and afflicts all age groups, with a mean presentation at 55.3 years (standard deviation, 21.6 years; range, 15–79 years). All reported cases describe patients with locally destructive disease, with the most common symptoms being nasal obstruction, epistaxis, and facial pain. The maxillary sinus was involved most commonly, followed by the ethmoid sinus and nasal septum. Alt et al. reported isolated sphenoid sinus involvement with symptoms of constant frontal headaches. Ishida et al. found concomitant parotid gland IgG4-RSD in addition to disease of the right maxillary sinus and nasal septum; however, isolated sinonasal disease was found in the remainder of patients.

To establish the diagnosis, a tissue biopsy rather than primary resection was performed in the majority of

---

**Table 1** Quantitative cutoff values for the diagnosis of systemic IgG4-RSD*

|                          | Sensitivity, % | Specificity, % |
|--------------------------|----------------|----------------|
| Serum IgG4 level, >135 mg/dL | 97.0           | 79.6           |
| Serum IgG4: IgG ratio, >8% | 95.5           | 87.5           |
| >10 IgG4+ cells per high-powered field | 100            | 38.1           |
| IgG4+ cell to IgG+ cell ratio, >40% | 94.4           | 85.7           |

*IgG4 = immunoglobulin G4; RSD = related sclerosing disease.*

*From Ref. 3.*
patients. After surgery, a systemic steroid was immediately started in several patients; although the dosage and duration was not consistent. Alt et al. noted recurrent and/or recidivistic disease 2 months after surgery of primary debulking; thus, fluticasone was initiated with no reported progression. Lindau et al. and Prabhu et al. described the use of rituximab in patients with poor response to oral steroids after biopsy.

**DISCUSSION**

The prototype of IgG4-RSD has become IgG4–related sclerosing pancreatitis, also known as autoimmune pancreatitis. Extrapancreatic pathology has been reported in many organ systems, including regions within the head and neck. Although most cases of IgG4-RSD are systemic, clinicians should be aware of possible isolated sinonasal disease. As in our case, most cases of paranasal IgG4-RSD report locally destructive disease. Many of the presenting symptoms mimic other forms of rhinitis or rhinosinusitis with rhinorrhea, nasal obstruction, facial pressure, and epistaxis being the most common. Based on symptomatology, this could prompt the clinician to initiate intranasal steroid sprays that possibly aid in the treatment of both rhinosinusitis and paranasal IgG4-RSD, thus potentially delaying the diagnosis.

Endoscopic biopsy for immunohistochemistry may be the primary role of surgery. A characteristic histologic appearance with marked plasma cell IgG4 expression supports a diagnosis of IgG4-RSD. Serum IgG4 levels are potentially misleading because IgG subtypes can be elevated in other inflammatory conditions. In the cases reviewed, most surgeons performed a tissue biopsy rather than complete excision of the lesion. In our case, a complete excision was performed. There does not seem to be a correlation between the extent of biopsy and disease recurrence (i.e., biopsy versus excisional biopsy). Therefore, it is unclear whether an attempt at surgical excision needs to be or should be performed.

Due to limited evidence, the management of sclerosing diseases that affect the sinuses is largely based on extrapolations from other organ systems. Currently, the suggested treatment for systemic IgG4-RSD is an oral corticosteroid taper over several weeks, the dose and duration of which is poorly defined. Except for two patients, in the cases reviewed, there were no recurrences or progression of disease reported in patients started on oral prednisolone soon after a tissue diagnosis. However, the follow-up time documented was not consistent or standardized, the sample size was small, and, therefore, an evidence-base recommendation was lacking. One case noted recidivistic disease 2 months after surgery, and fluticasone intranasal spray was started with no progression reported. In cases isolated to the paranasal sinuses, a nasal steroid irrigation, e.g., budesonide 0.5 mg in 240 mL normal saline solution, could target nasal symptoms; although, this has never been studied or reported.

Disease surveillance should be directed by clinical examination and symptomatology, including endoscopic examination and, possibly, imaging. Periodic serology studies (i.e., IgG4 levels) may be indicated with suspicion of systemic involvement. Further, there is no standard for treating recurrence; re-treatment with high-dose corticosteroid is an option, alternatively, immunomodulating medications (i.e., rituximab) may be beneficial in refractory cases. In our case, there had been no recurrence of disease after 12 months of observation.

**CONCLUSION**

Only several cases of IgG4-RSD isolated to the paranasal sinuses have been described in the literature. The disease typically presents as a nasal lesion with obstructive symptoms. Imaging is nonspecific and demonstrates an expansive and erosive process, usually without infiltrative characteristics. Surgery at minimum provides tissue for histologic analysis but may provide relief of symptomatic nasal obstruction or may alleviate mucociliary obstruction and restore effective paranasal sinus ventilation when more extensive excisional procedures are performed. There is a paucity of evidence to guide management strategies. Local and systemic medical therapies are unproven and poorly studied; however, most reports describe symptom control and improved endoscopic appearance, with systemic steroid use. It is unclear whether IgG4-RSD lesions of the sinuses recur and, if so, when. Therefore, evidence-based recommendations for follow-up are lacking. It seems prudent that endoscopic surveillance
| Study, y | Country | Age, y/Sex | Location | Chief Concern | Serum IgG4 level, mg/dL | Immunohistochemistry | Treatment | Recurrence |
|---------|---------|------------|----------|---------------|-------------------------|----------------------|------------|------------|
| Ishida et al., 2009 | Japan | 73/M | Right maxillary sinus, nasal septum, and parotid gland | Nasal obstruction | 63.4 | IgG4 expression in >70% of plasma cells | Resection of the maxillary sinus tumor and resection of the parotid tumor 6 wk later | No recurrence in the maxillary sinus or parotid; however, nasal septal mass was found 1 year later |
| Pace and Ward, 2010 | United Kingdom | 73/M | Right maxillary sinus | Facial swelling | Not reported | IgG4 expression in >20% of plasma cells | Biopsy and 20 mg/day prednisolone | No recurrence at 5 mo |
| Ikeda et al., 2010 | Japan | 50/F | Left maxillary and ethmoid sinuses | Bloody rhinorrhea and postnasal drip | 258 | Numerous IgG4+ plasma cells | Biopsy and 30 mg/day of prednisolone | No recurrence at 6 mo |
| Sasaki et al., 2012 | Japan | 71/M | Bilateral maxillary sinuses and nasal cavity | Nasal occlusion and facial swelling | 114 | Plasma cells expressing IgG4 | Biopsy and oral prednisolone for 18 mo (tapered to 10 mg/day from an initial dose of 40 mg/day) | Tumor remained stable |
| Alt et al., 2012 | USA | 38/F | Sphenoid sinus | Frontal headaches | 20 | >150 IgG4+ plasma cells/hpf | Debulking primarily and fluticasone was initiated when recurrence was noted | Recurrence noted at 2 mo |
| Lindau et al., 2013 | USA | 69/M | Maxillary sinus | Chronic sinusitis and diplopia | 74 | >30 IgG4+ plasma cells/hpf | Debulking and prednisone, then dexamethasone pulse therapy and rituximab | Progression on dexamethasone alone; improvement when on dexamethasone with rituximab |
| Prabhu et al., 2014 | India | 15/F | Nasal septum, right lateral nasal wall, extension into the right maxillary sinus | Nasal obstruction and epistaxis | 206 | IgG4 expression in 50% of plasma cells | Biopsy and prednisolone | No recurrence noted |
| Prabhu et al., 2014 | India | 15/F | Right lateral nasal wall, nasal roof, nasal septum, right maxillary, ethmoid, and sphenoid sinuses | Bloody rhinorrhea, facial swelling, and trismus | 579 | IgG4 expression in 50% of plasma cells and >30 IgG4+ plasma cells/hpf | Biopsy and prednisolone (1 mg/kg/day) and rituximab (two intravenous infusions of 600 mg, 15 days apart) | Progression of disease, rituximab started |
| Cain et al., 2014 | USA | 62/F | Nasal septum and ethmoid sinuses | Epistaxis | Not reported | Approaching 50 IgG4+ plasma cells/hpf | Biopsy and prednisone 20 mg/day | No progression |
| Cain et al., 2014 | USA | 79/M | Anterior inferior nasal septum with erosion of premaxilla | Epistaxis | Not reported | 30–50 IgG4+ plasma cells/hpf | Biopsy and nasal budesonide (0.5 μg in 240 mL of normal saline solution) because the patient declined systemic steroids | Without progression |
| Song et al., 2015 | USA | 72/M | Maxillary and anterior ethmoid sinuses | Exophthalmos, periorbital pain, and epiphora | 94.5 | >50 IgG4+ plasma cells/hpf | Biopsy and prednisone 40 mg/day tapered over 3 mo | Resolution at 6 mo |
| Vandjelovic and Humphreys, 2015 | USA | 46/M | Ethmoid sinus with extension into the frontal recess | Epistaxis, facial pain, nasal congestion, rhinorrhea, and nasal crusting | Did not obtain | IgG4 expression in >50% of plasma cells | Excisional biopsy and prednisone 30 mg/day for 1 mo, with gradual taper; nasal saline solution rinses | No recurrence at 12 mo |

IgG4 = immunoglobulin G4; RSD = related sclerosing disease; hpf = high-powered field.
continues yearly or as directed by symptomatology. Imaging may be best reserved for those with clinical evidence of recurrence.

ACKNOWLEDGMENTS

We thank Aaron Prussin, M.D., and Mark R. Wick, M.D. for their support in the workup and management of the patient.

REFERENCES

1. French M. Serum IgG subclasses in normal adults. Monogr Allergy 19:100–107, 1986.
2. Zen Y, Fujii T, Harada K, et al. Th2 and regulatory immune reactions are increased in immunoglobulin G4-related sclerosing pancreatitis and cholangitis. Hepatology 45:1538–1546, 2007.
3. Masaki Y, Kurose N, Yamamoto M, et al. Cutoff values of serum IgG4 and histopathological IgG4+ plasma cells for diagnosis of patients with IgG4-related disease. Int J Rheumatol 2012:580814, 2012.
4. Deshpande V, Zen Y, Chan JK, et al. Consensus statement on the pathology of IgG4-related disease. Mod Pathol 25:1181–1192, 2012.
5. Ishida M, Hotta M, Kushima R, et al. Multiple IgG4-related sclerosing lesions in the maxillary sinus, parotid gland and nasal septum. Pathol Int 59:670–675, 2009.
6. Alt JA, Whitaker GT, Allan RW, and Vaysberg M. Locally destructive skull base lesion: IgG4-related sclerosing disease. Allergy Rhinol (Providence) 3:e41–e45, 2012.
7. Lindau RH, Su YB, Kobayashi R, and Smith RB. Immunoglobulin G4-related sclerosing disease of the paranasal sinus. Head Neck 35:E321–E324, 2013.
8. Prabhu SM, Yadav V, Irodi A, et al. IgG4-related disease with sinonasal involvement: A case series. Indian J Radiol Imaging 24:117–120, 2014.
9. Kamisawa T, Funata N, Hayashi Y, et al. A new clinicopathological entity of IgG4-related autoimmune disease. J Gastroenterol 38:982–984, 2003.
10. Kitagawa S, Zen Y, Harada K, et al. Abundant IgG4-positive plasma cell infiltration characterizes chronic sclerosing sialadenitis (Kuttner’s tumor). Am J Surg Pathol 29:783–791, 2005.
11. Cheuk W, Yuen HK, and Chan JK. Chronic sclerosing dacyroadenitis: Part of the spectrum of IgG4-related sclerosing disease? Am J Surg Pathol 31:643–645, 2007.
12. Sah RP, and Chari ST. Serologic issues in IgG4-related systemic disease and autoimmune pancreatitis. Curr Opin Rheumatol 23:108–113, 2011.
13. Kamisawa T, and Okamoto A. IgG4-related sclerosing disease. World J Gastroenterol 14:3948–3955, 2008.
14. Khosroshahi A, Carruthers MN, Deshpande V, et al. Rituximab for the treatment of IgG4-related disease: lessons from 10 consecutive patients. Medicine (Baltimore) 91:57–66, 2012.
15. Cain RB, Colby TV, Balan V, et al. Perplexing lesions of the sinonasal cavity and skull base: IgG4-related and similar inflammatory diseases. Otolaryngol Head Neck Surg 151:496–502, 2014.
16. Pace C, and Ward S. A rare case of IgG4-related sclerosing disease of the maxillary sinus associated with bone destruction. J Oral Maxillofac Surg 68:2591–2593, 2010.
17. Ikeda R, Awataguchi T, Shoji F, and Oshima T. A case of paranasal sinus lesions in IgG4-related sclerosing disease. Otolaryngol Head Neck Surg 142:458–459, 2010.
18. Sasaki T, Takahashi K, Mineta M, et al. Immunoglobulin G4-related sclerosing disease mimicking invasive tumor in the nasal cavity and paranasal sinuses. AJNR Am J Neuroradiol 33:E19–E20, 2012.
19. Song BH, Baiyee D, and Liang J. A rare and emerging entity: Sinonasal IgG4-related sclerosing disease. Allergy Rhinol (Providence) 6:151–157, 2015.